1,7-phenanthroline has been researched along with Vascular Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, Z; Xiao, F; Yu, S; Zhang, H; Zheng, M; Zhong, B | 1 |
| Chang, KC; Chung, HT; Joe, Y; Kang, SS; Kim, HJ; Kim, S; Park, C; Ryoo, S; Ryter, SW; Ryu, DG; Uddin, MJ; Zheng, M | 1 |
1 review(s) available for 1,7-phenanthroline and Vascular Diseases
| Article | Year |
|---|---|
The quality of randomized controlled trials on DanShen in the treatment of ischemic vascular disease.
Topics: Analysis of Variance; Cardiovascular Agents; Drugs, Chinese Herbal; Humans; Ischemia; Phenanthrolines; Randomized Controlled Trials as Topic; Salvia miltiorrhiza; Vascular Diseases | 2009 |
1 other study(ies) available for 1,7-phenanthroline and Vascular Diseases
| Article | Year |
|---|---|
Salvianolic acid B exerts vasoprotective effects through the modulation of heme oxygenase-1 and arginase activities.
Topics: Animals; Arginase; Benzofurans; Blotting, Western; Drugs, Chinese Herbal; Electrophoretic Mobility Shift Assay; Fibrinolytic Agents; Heme Oxygenase-1; Humans; Lipopolysaccharides; Macrophages; Male; Mice; Mice, Inbred C57BL; Nitric Oxide; Nitric Oxide Synthase Type II; Phenanthrolines; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; Salvia miltiorrhiza; Tumor Necrosis Factor-alpha; Vascular Diseases | 2012 |